

References

L-223

1. Stasi C, Milani S. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. *World J Gastroenterol*. 2016;22(4):1711-1720.
2. BioPredictive. Technical Recommendations for FibroTest and FibroMax assays: A guide for biologists and laboratories. Updated March 23, 2016.
3. BioPredictive. Practice of FibroTest for hepatitis B.
4. World Health Organization (WHO). Guidelines for the prevention, care and treatment of persons with chronic hepatitis C infection. Geneva (Switzerland): World Health Organization (WHO); 2016 Apr.
5. World Health Organization (WHO). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva (Switzerland): World Health Organization (WHO); 2015 Mar.
6. European Association for Study of Liver. EASL-ALEH Clinical Practice Guidelines: Noninvasive tests for evaluation of liver disease severity and prognosis. *J Hepatol*. 2015;63(1):237-264.
7. World Gastroenterology Organization (WGO). Esophageal varices. Milwaukee (WI): World Gastroenterology Organization (WGO); 2014.
8. Wilkins E, Nelson M, Agarwal K, et al. British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. *HIV Med*. 2013;14(Suppl 4):1-71.
9. Houot M, Ngo Y, Munteanu M, et al. Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. *Aliment Pharmacol Ther*. 2016 Jan;43(1):16-29.
10. Salkic NN, Jovanovic P, Hauser G, Brcic M. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. *Am J Gastroenterol*. 2014;109(6):796-809.
11. Stevenson M, Lloyd-Jones M, Morgan MY, Wong R. Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation. *Health Technol Assess*. 2012;16(4).
12. Poynard T, Lassailly G, Diaz E, et al; FLIP consortium. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. *PLoS One*. 2012;7(3):e30325.
13. Naveau S, ESOH BM, Ghinoiu M, et al. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease. *Eur J Gastroenterol Hepatol*. 2014;26(4):404-411.

14. Perazzo H, Munteanu M, Ngo Y, et al; FLIP Consortium. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. *Aliment Pharmacol Ther.* 2014;40(9):1081- 1093.
15. Munteanu M, Tiniakos D, Anstee Q, et al; FLIP Consortium and the FibroFrance Group. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. *Aliment Pharmacol Ther.* 2016;44(8):877-889.
16. Cheng J, Hou J, Ding H, et al. Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B. *PLoS One.* 2015;10(12):e0144425.
17. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC Med Res Methodol.* 2007;7:10.